Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoImmunome for Stage III/IV Ovarian Carcinoma
NCT02933073Phase 1Terminated
- Sponsor
- UConn Health
- Start
- Nov 2016
- Primary completion
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OncoImmunome in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by UConn Health. Primary endpoint: Treatment-related adverse events at 5 years. Started Nov 2016; status: terminated.
02
Drugs
OncoImmunome
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02933073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933073.